Therapy News and Research

RSS

Six-minute walking distance test effectively determines disease severity in COPD

The six-minute walking distance test, a test that measures a patient's ability to tolerate exercise and physical activity, is an effective tool for understanding disease severity in patients with chronic obstructive pulmonary disease, according to a three-year global study of patients with COPD sponsored by drug manufacturer GlaxoSmithKline.

16 May 2011

Study: HIV treatment drugs slash transmission risk

AIDS researchers offered evidence backing up the long-standing idea that people infected with HIV who are being treated are much less likely to transmit the virus than those who are not on drugs. This finding is being hailed as a breakthrough.

16 May 2011

Volcano to share intravascular therapy guidance and optimization solutions at EuroPCR

Volcano Corporation today announced its participation in the Paris course for Revascularization from May 17 – 20. Volcano's focus will be on highlighting the strength of its product portfolio, which includes innovative devices like the Vascular Imaging Balloon Catheter, and its sponsorship of a symposium that highlights the use and value of Precision Guided Therapy in clinical practice today.

16 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Substances produced by living organisms found in nature-so-called "natural products"-have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

16 May 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Preliminary results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday " in what is being hailed as a breakthrough in HIV prevention," the Los Angeles Times reports.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

Loyola earns Joint Commission certification for heart pump therapy

Loyola University Hospital has been certified by the Joint Commission to begin implanting heart pumps known as left ventricular assist devices (LVADs) as permanent therapy for advanced heart failure.

16 May 2011

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Matthew Feddersen and Blake Marggraff from Lafayette, Calif. were awarded the top prize at the Intel International Science and Engineering Fair, a program of Society for Science & the Public. They received $75,000 and the Gordon E. Moore Award, in honor of the Intel co-founder and retired chairman and CEO, for developing a potentially more effective and less expensive cancer treatment that places tin metal near a tumor before radiation therapy.

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment.

16 May 2011

AIDS spread prevention by vaccine and anti HIV drugs

A latest vaccine against HIV/AIDS has shown to be effective in monkeys and has protected macaques the most widespread primate genus, against the monkey equivalent of HIV, Simian immunodeficiency virus (SIV). This could provide a fresh approach to an HIV vaccine, a study suggests. US researchers say the vaccine offered protection to 13 of 24 Rhesus macaques treated in the experiment. In 12 of the monkeys, the vaccine was still effective 12 months later.

15 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

China's SFDA approves TPI anti-diabetic drug Gliclazide

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets.

13 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

PBS' NewsHour reports on Ukraine's efforts to fight HIV/AIDS

PBS' NewsHour on Wednesday featured a story on HIV/AIDS in the Ukraine, which has Europe's highest HIV/AIDS rate, increasing fears that the epidemic could spread to neighboring countries. The story focuses on attempts to implement drug substitution therapy programs for injecting drug users and prevent the virus from moving into the general population.

13 May 2011

Researchers untangle two distinct ways in which tumor-suppressor protein works

Researchers at the Stanford University School of Medicine have untangled two distinct ways in which a common, naturally occurring "tumor-suppressor" protein works.

13 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

Therapy News and Research

Six-minute walking distance test effectively determines disease severity in COPD

Study: HIV treatment drugs slash transmission risk

Volcano to share intravascular therapy guidance and optimization solutions at EuroPCR

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

New York Academy of Sciences and Zeltia to host marine drug discovery forum on May 20, 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Loyola earns Joint Commission certification for heart pump therapy

Young scientists receive Intel Foundation top prize for groundbreaking cancer work

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Obese men may face high risk of prostate cancer progression

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

AIDS spread prevention by vaccine and anti HIV drugs

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

China's SFDA approves TPI anti-diabetic drug Gliclazide

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

PBS' NewsHour reports on Ukraine's efforts to fight HIV/AIDS

Researchers untangle two distinct ways in which tumor-suppressor protein works

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News